Compare DRIO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | XLO |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 49.8M |
| IPO Year | 2013 | 2021 |
| Metric | DRIO | XLO |
|---|---|---|
| Price | $7.30 | $9.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $28.00 |
| AVG Volume (30 Days) | 5.4K | ★ 26.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1559.02 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | $7,394,000.00 | ★ $43,766,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $47.58 | $168.77 |
| P/E Ratio | $5.67 | ★ N/A |
| Revenue Growth | 43.02 | ★ 589.88 |
| 52 Week Low | $0.38 | $0.46 |
| 52 Week High | $17.74 | $9.25 |
| Indicator | DRIO | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 65.76 |
| Support Level | $6.16 | $7.47 |
| Resistance Level | $9.46 | N/A |
| Average True Range (ATR) | 0.37 | 0.50 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 11.00 | 87.24 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.